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Introduction
Anaphylaxis is a severe form of allergic reaction resulting in sys-
temic symptoms, including respiratory, gastrointestinal, or cuta-
neous manifestations. This may include hypotension, hypoxia, 
and poor end-organ perfusion (1). This allergic adverse reaction 
is typically precipitated when IgE-bound mast cells (MCs) come 
in contact with allergens, resulting in extensive degranulation of 
these cells. Increasingly, these reactions are directed at antigenic 
moieties that are routinely encountered in foods or in therapeutic 
drugs. Thus, approaches to treat or avoid potentially deadly reac-
tions to these allergens are sorely needed. Rush desensitization 
(DS) is a widely used clinical protocol that rapidly enables aller-
gic individuals to tolerate various foods or drugs to which they are 
hyperresponsive. The procedure involves exposing reactive sub-
jects serially to increasing doses of the relevant antigen (Ag) over 
a short interval of time, typically with minutes or hours between 
doses, which renders the individual temporarily hyporesponsive 
to the Ag (2). Patients allergic to crucial antibiotics (3) or chemo-
therapy (4) are routinely desensitized by DS protocols before they 
are exposed to the therapeutic agent. Oral DS has also been used to 
allow patients to tolerate the first dose of immunotherapy regimens 
for certain food allergies (5). In spite of its widespread usage, the 
underlying mechanism of DS remains to be resolved. This limita-
tion has severely hampered the development of alternate and per-
haps more convenient approaches to tolerize reactive individuals.
MCs are now widely believed to be the primary target of the 
DS protocol, as reactivity to MC-dependent skin prick tests is 
reduced or sometimes disappears after desensitization (6). These 
cells constitutively express high levels of FcεRI, the high-affinity 
receptor for IgE. Upon allergen (antigen)-mediated activation, 
MCs rapidly release a collection of inflammatory mediators that 
are prestored within their granules. Many of these prestored medi-
ators, such as histamine, serine proteases, and heparin, have been 
implicated in the pathology of anaphylactic shock (reviewed in 
refs. 7, 8). Additionally, activated MCs mediate de novo synthesis 
and secretion of a wide range of mediators that exacerbate sys-
temic inflammation in multiple ways, including the recruitment of 
other inflammatory cell types such as neutrophils (9) and eosin-
ophils (10). These prestored and de novo–synthesized mediators 
of MCs collectively account for much of the pathology associated 
with severe allergic reactions.
MC signaling events upon allergic challenge begin with the 
engagement of IgE bound in the MC surface by the Ag. Aggrega-
tion of receptors by cross-linking with Ag stabilizes their association 
with cholesterol-rich lipid rafts, which function as signaling plat-
forms for further downstream signaling. Within these rafts, activa-
tion of Src family kinases and phosphorylation of immuno receptor 
tyrosine-based activation motifs of FcεRI (11) by LYN kinase initiate 
a tyrosine phosphorylation cascade and the recruitment of the sig-
naling adaptor LAT (12). This culminates in the activation of PLCγ, 
which catalyzes the conversion of phosphatidylinositol-4,5-phos-
phate (PIP2) to the second messengers inositol trisphosphate (IP3) 
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resentative in vivo and in vitro models of DS. Before establishing 
an in vivo DS protocol, it was necessary to develop and validate 
a model of passive anaphylaxis with demonstrable MC involve-
ment. Briefly, WT and MC-deficient mice (KitW-sh/KitW-sh mice, 
hereafter referred to as Wsh mice) were sensitized with 10 μg 
anti-TNP (trinitrophenyl) IgE i.p., then challenged i.p. with 500 
μg TNP-OVA. Rectal temperatures were measured as an indica-
tion of anaphylaxis. MC-deficient Wsh mice were refractory to 
anaphylaxis, while WT mice showed a drastic drop in temperature 
15–30 minutes after challenge (Figure 1A). Using this model, we 
sought to establish an oral DS protocol to protect against anaphy-
laxis. We gavaged IgE-sensitized WT mice with increasing doses 
of Ag (Table 1) or with equivalent volumes of PBS at 30-minute 
intervals. During the desensitization process, all groups showed 
no significant changes in core body temperature. At the end of the 
desensitization or control treatment, mice were challenged i.p. 
with 500 μg of TNP-OVA in PBS. Control (PBS-treated, IgE-sen-
sitized) mice showed a sharp decrease in core body temperature 
after challenge, indicating anaphylaxis, while desensitized mice 
subjected to DS exhibited very limited changes in temperature in 
response to challenge, which were not significantly different from 
those in unsensitized mice (Figure 1B). To confirm that there was 
limited MC degranulation during the desensitization process, we 
stained peritoneal lavages obtained from control, Ag-challenged, 
or desensitized mice with toluidine blue, which stains MC gran-
ules a deep purple color. As expected, Ag-challenged mice had a 
significantly higher percentage of partially or fully degranulated 
MCs as observed via microscopy, while IgE-alone and desensitized 
mice had mostly fully granulated MCs (Figure 1C). To further con-
firm MC involvement in our model, mice were bled 30 minutes 
after Ag challenge of desensitized or control mice for serum anal-
ysis of murine mast cell protease 1 (mMCPT-1), a known MC gran-
ule–associated chymase released during anaphylaxis (27). Mice 
that had been sensitized with IgE but were not Ag challenged (IgE 
alone), as well as unsensitized PBS-injected mice (PBS), had very 
low levels of serum mMCPT-1 (Figure 1D). As expected, Ag-chal-
lenged mice had very high levels of serum mMCPT-1. Importantly, 
desensitized mice had levels of serum mMCPT-1 not significantly 
different from those seen with baseline PBS despite oral adminis-
tration of Ag during desensitization and subsequent i.p. challenge. 
Thus, our in vivo model of DS was effective, as it protected mice 
from anaphylaxis by preventing MC degranulation.
Next we sought to develop an in vitro model for DS that was 
applicable for murine bone marrow–derived mast cells (BMMCs) 
as well the RBL-2H3 cell line (Figure 1E and Table 2). The model we 
developed was adapted from Sancho-Serra et al. (26). MC degran-
ulation was assessed by measurement of extracellular levels of the 
granule component β-hexosaminidase. The extent of hexosamini-
dase release (degranulation) was expressed as a percentage release 
over total hexosaminidase present in cells. IgE-sensitized BMMCs 
were either desensitized or control treated before cross-linking of 
IgE/FcεRI with anti-IgE or Ag. Upon Ag or anti-IgE challenge, con-
trol MCs degranulated significantly (Figure 1E), while desensitized 
MCs exhibited limited degranulation response to activation by 
either Ag or anti-IgE. Having validated the efficacy of this in vitro 
model of DS, we used this model for our subsequent studies to elu-
cidate the underling basis for MC desensitization.
and diacylglycerol. Binding of IP3 to receptors on the endoplasmic 
reticulum results in the emptying of intracellular Ca2+ stores and 
subsequent store-operated Ca2+ entry (SOCE), which results in the 
sustained elevation of intracellular Ca2+ required for exocytosis 
of MC granules (13). A second, LAT-independent pathway via the 
kinase FYN also contributes synergistically to degranulation (14). 
Upon FcεRI cross-linking, MCs also undergo dramatic morpholog-
ical changes orchestrated by dynamic reorganization of the cyto-
skeleton. The actin cytoskeleton has been implicated in regulatory 
exocytosis in a variety of cell types, playing often complex and con-
tradictory roles (reviewed in ref. 15). In MCs (16) and other secretory 
cell types (17), cortical actin is thought to be a barrier to exocyto-
sis, and has to be redistributed before fusion of membrane-bound 
granules to the plasma membrane can occur. Polymerized actin can 
also act as an anchor for secretory vesicles (18) as well as a track for 
actively trafficking secretory vesicles before exocytosis (15). Impor-
tantly, actin may play negative regulatory roles in cellular signaling, 
and its reorganization is required for cell activation events such as 
the initiation of B cell receptor signaling (reviewed in ref. 19). Addi-
tionally, actin can serve as a crucial modulator of Ca2+ responses 
in hematopoietic cells, which require SOCE for a variety of down-
stream effector responses. In T cells, for example, inhibiting actin 
polymerization sustains elevated intracellular Ca2+ levels, augment-
ing cytokine responses (20). The actin regulator WAVE2 has also 
been reported to be important for SOCE in T cells (21). In MCs, sev-
eral studies using global actin inhibitors (22, 23) as well as a recent 
study using mice deficient in the actin regulatory protein drebrin 1 
(24) have pointed to the pivotal role of the actin cytoskeleton in 
influencing Ca2+ responses to IgE/antigen.
Although several recent studies have attempted to examine 
the underlying mechanisms regarding DS of MCs, there is as yet 
no consensus in the literature. Some reports have attributed MC 
hyporesponsiveness following DS to depletion of cell surface IgE 
following internalization of IgE/FcεRI complexes (25), while oth-
ers have reported the opposite, namely reduced FcεRI internal-
ization and impaired early and late MC responses in desensitized 
MCs compared with untreated MCs (26). In view of the discor-
dance in opinion regarding the underlying basis for DS, we ini-
tiated a study to address this question. We observed that in spite 
of active endocytosis of IgE/FcεRI complexes during DS, appre-
ciable amounts of residual IgE molecules capable of binding Ag 
were still present on the surface of desensitized MCs, indicating 
that the hyporesponsiveness of these cells to Ag was not due to 
depletion of surface IgE. Furthermore, FcεRI in desensitized MCs 
was still capable of signal transduction, which was inconsistent 
with previous reports implying abrogation of IgE-mediated sig-
naling following complete desensitization of MCs. Significantly, 
we found that the actin cytoskeleton in MCs was markedly reor-
ganized during DS, and this alteration appeared to negatively 
impact Ca2+ mobilization, a key requirement for MC degranula-
tion, following FcεRI-mediated signaling. This observation impli-
cates the displacement of the cellular actin cytoskeleton as the 
underlying reason for MC desensitization following DS.
Results
Establishing in vivo and in vitro models of DS. To address the under-
lying basis for MC desensitization, we first sought to establish rep-
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c-kit+ cells from IgE-sensitized mice bound high amounts of fluo-
rescent Ag, due to high levels of surface IgE. MCs from Ag-chal-
lenged mice had the lowest fluorescence, reflecting internalization 
of IgE resulting from Ag challenge, a well-described consequence 
of IgE-mediated MC activation (29). Surprisingly, c-kit+ cells from 
desensitized mice bound high levels of fluorescent Ag, significant-
ly more than Ag-challenged mice. This comparatively high bind-
ing capacity to additional Ag suggested that surface IgE was still 
plentiful, in spite of IgE internalized during the DS protocol. To 
support our findings, we repeated this experiment in vitro using 
BMMCs. IgE-sensitized BMMCs were desensitized, challenged 
with Ag, or left unchallenged, before being collected and incu-
Functional IgE remains on the surfaces of desensitized MCs. Pre-
vious studies have suggested that MC desensitization was attrib-
utable to the internalization of IgE antibodies during this process. 
If this were the case, then there should be limited IgE left on these 
cell surfaces capable of binding sufficient Ag for activation. To test 
the residual Ag-binding ability of desensitized cells, we collected 
peritoneal lavages from IgE-sensitized mice that had been desen-
sitized (DS), Ag challenged (Ag), or unchallenged (IgE). Peritoneal 
cells obtained from the lavage were incubated with Alexa Fluor 
647–labeled (A647-labeled) TNP-OVA ex vivo (Figure 2A), and the 
extent of Ag binding was assessed by FACS, with gating for c-kit+ 
cells, which in the peritoneal cavity are all MCs (28). As expected, 
Figure 1. In vivo and in vitro models of desensitization. (A–D) Mice were sensitized i.p. with 10 μg IgE and challenged i.p. with 500 μg TNP-OVA. Tem-
peratures were measured rectally and expressed as change in initial temperature. (A) MC-deficient Wsh mice and WT mice were challenged with Ag and 
monitored for 90 minutes (n = 3–4). (B) Mice were orally desensitized or mock treated for 8 doses, each spaced 30 minutes apart. Thirty minutes after 
the last dose, mice were challenged with Ag and rectal temperatures recorded every 15 minutes. Mice were given saline throughout (n = 5). (C) Peritoneal 
lavage was obtained at the end of desensitization or equivalent period of i.p. Ag challenge or PBS treatment (n = 4–5 per group). Lavage was cytospun 
and stained with toluidine blue, and the percentage of degranulated MCs was counted in 5 random fields per cytospin. Representative images at ×40 
magnification are shown. (D) Mice were bled at the end of desensitization or Ag challenge as in B and serum analyzed via ELISA for MCPT-1 (n = 5). 5 × 105 
IgE-sensitized BMMCs in triplicate were desensitized or control treated, then challenged with buffer, 10 ng/ml Ag, or 0.5 μg/ml anti-IgE. β-Hexosamini-
dase release was measured and expressed as a percentage of total. Data were analyzed via repeated-measures ANOVA (A and B), 1-way ANOVA (C and D), 
or 2-way ANOVA (E). Error bars represent SEM. *P < 0.05, ***P < 0.001.
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The residual Ag-binding capacity of desensitized MCs made 
us speculate that desensitized MCs could perhaps recover the abil-
ity to degranulate in response to Ag challenge, much as the effects 
of DS in clinical settings are temporary, with subjects regaining 
their reactivity to the allergen after the desensitization process is 
discontinued (30). In this way, we could also further demonstrate 
that desensitization of MCs was not due to lack of cell surface IgE 
by showing that recovery of Ag sensitivity can occur even without 
addition of fresh IgE. For this experiment, IgE-sensitized BMMCs 
were desensitized, challenged with Ag, or left unchallenged, then 
washed multiple times, resuspended in BMMC culture medium, 
and allowed to recover without any additional IgE included in 
the medium. After 0, 24, 48, or 72 hours of incubation at 37°C, 
MCs were challenged with 10 ng/ml of Ag. As expected, cells 
that were not initially challenged with Ag at 0 hours (IgE group) 
had the highest degranulation responses when challenged at 
24, 48, or 72 hours. Notably, the degranulation responses of this 
group increased with time, a result that might be attributable to 
bated with A647-labeled TNP-OVA. After extensive washing, 
cells were processed for FACS (Figure 2B). As expected, based on 
A647 fluorescence, untreated (IgE alone) BMMCs had the highest 
Ag binding, as a result of having the highest surface IgE. Ag-chal-
lenged MCs showed the least Ag binding. Desensitized BMMCs 
showed almost as much Ag binding as IgE-only cells, though the 
decrease was still statistically significant. Importantly, desensi-
tized MCs could bind significantly more Ag than Ag-challenged 
MCs. BMMCs without IgE, included as a negative staining con-
trol, did not bind Ag significantly. These data thus suggested that 
surface IgE was not completely internalized following the desen-
sitization process, and enough IgE remained on the cell surface to 
bind Ag that could potentially cause degranulation. Indeed, we 
have found that degranulation does not decrease proportionately 
with decreasing concentrations of sensitizing IgE, indicating that 
even low amounts of surface IgE are sufficient to trigger degran-
ulation (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI87492DS1).
Figure 2. Complete depletion of surface IgE does not occur with desensitization. (A) IgE-sensitized mice were desensitized (DS), challenged with 
antigen (Ag), or injected with PBS (IgE). At the end of desensitization, mice were sacrificed for peritoneal lavage. Lavage cells were incubated with 
A647-labeled TNP-OVA for 1 hour on ice, then washed 5 times with PBS before fixation and assay via FACS. Data were expressed as fold median fluo-
rescence intensity (MFI) over IgE alone. Data are combined from 2 experiments (n = 10). (B) 5 × 105 IgE-sensitized BMMCs per sample in quintuplicate 
were desensitized (blue), Ag challenged (red), or untreated (green), then labeled with A647–TNP-OVA as in A. BMMCs without IgE were also incubated 
with labeled TNP-OVA as control (gray). A histogram representative of at least 3 experiments is shown. (C) 5 × 105 BMMCs per sample of IgE-alone (IgE), 
Ag-challenged (Ag), or desensitized (DS) cells were washed 3 times in PBS before resuspension in 500 μl RPMI without IgE. Zero to 72 hours later, cells 
were collected and challenged with 10 ng/ml Ag. Degranulation was measured using a β-hexosaminidase assay. (D) Control (IgE), Ag-challenged (Ag), or 
desensitized (DS) cells were incubated for 0 or 48 hours before being assayed for surface staining of IgE via FACS. Data are representative of at least 3 
independent experiments. Data were analyzed via 1-way (A) or 2-way (C and D) ANOVA. Error bars indicate SEM. *P < 0.05, **P < 0.01, ***P < 0.001,  
#P < 0.001 compared with all other groups.
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to the cell surface. To further establish that the inability of desen-
sitized cells to respond to Ag was not due to the lack of IgE, we 
resensitized desensitized BMMCs with 0.5 μg/ml IgE at both 0 
and 24 hours after desensitization. We did not find a difference 
between resensitized and untreated desensitized cells, as both 
groups showed little degranulation in response to Ag challenge 
compared with controls (Supplemental Figure 2). However, the 
lack of degranulation may also be due to the inability of freshly 
added IgE to bind to the MC surface, owing to the lack of unoccu-
pied FcεRI. Cumulatively, these observations support the notion 
that absence of cell surface IgE to activate MCs is not the reason 
for the lack of response to Ag in desensitized cells.
Desensitized MCs transduce signals following Ag challenge despite 
abrogation of degranulation. Since residual IgE could be detected 
on MC surfaces even after desensitization, we sought to identify 
alternate mechanisms for MC desensitization. First, we inves-
tigated whether desensitized MCs still were able to transduce 
signals, even though degranulation failed to occur in response 
to additional Ag stimulation, as shown in Figure 1E. For this, we 
compared the kinetics of tyrosine phosphorylation of LYN, LAT, 
and ERK between IgE-sensitized and desensitized BMMCs, using 
the activation of these proteins as indicators of signaling at differ-
ent stages of the IgE/FcεRI signaling pathway. To do this, we used 
immunoblotting to assay the phosphorylation of these proteins at 
sites associated with their activation. Compared with untreated 
controls, Ag-stimulated MCs showed strong phosphorylation of 
LYN, LAT, and ERK within 5 minutes of exposure. Surprisingly, a 
similar pattern of phosphorylation was observed with desensitized 
cells challenged with Ag, with a significant increase in phosphory-
lated ERK, LAT, and LYN in comparison with IgE controls that was 
not significantly different from the increase seen in the respective 
Ag challenge groups (Figure 3). Thus, the inability of desensitized 
MCs to degranulate is not due to complete abrogation of IgE/
FcεRI signaling, as key components in this pathway were activated 
following Ag challenge.
the upregulation of granule components induced by prolonged 
incubation with IgE (31). By contrast, cells challenged with Ag at 0 
hours were unable to significantly degranulate to further Ag chal-
lenge until 72 hours. In desensitized cells, we determined that by 
48 hours after desensitization, BMMCs had regained their ability 
to significantly degranulate to Ag challenge, even without addition 
of fresh IgE (Figure 2C). To investigate whether this recovery by 
48 hours in desensitized MCs was due to recycling of IgE back to 
the cell surface, we incubated IgE-sensitized, Ag-stimulated, or 
desensitized BMMCs in IgE-free media for 0 or 48 hours before 
assessing surface IgE levels via FACS. As expected, unstimulated 
(IgE only) cells had the highest surface IgE levels for both time 
points, while Ag-stimulated cells had the lowest surface IgE. Over-
all, surface IgE declined over time in all groups. Desensitized MCs 
had intermediate surface IgE levels between those of Ag-treated 
and IgE control BMMCs, but there was no increase in surface IgE 
after 48 hours (Figure 2D). Therefore, we deduce that recovery 
likely was not due to recycling of previously endocytosed IgE back 
Table 1. In vivo desensitization protocol using oral gavage
Dose Volume (μl) Concentration (μg/ml)
1 100 0.005
2 100 0.05
3 100 0.5
4 100 5
5 100 50
6 100 500
7 100 2,500
8 100 5,000
Total 800 μl
At the end of the protocol, mice were challenged with 500 μg Ag i.p. Each 
desensitization dose was spaced 30 minutes apart.
Table 2. In vitro desensitization for β-hexosaminidase assay and cell lysate preparation
DNP-HSA OVA
DoseA VolumeB (μl) Concentration (ng/μl) Total Ag delivered (ng) Concentration (μg/μl) Total Ag delivered (μg)
1 1 1 0.001 0.1 0.0001
2 1 5 0.006 0.5 0.0006
3 1 5 0.011 0.5 0.0011
4 1 10 0.021 1 0.0021
5 1 10 0.031 1 0.0031
6 2 10 0.051 1 0.0051
7 2 20 0.091 2 0.0091
8 4 20 0.171 2 0.0171
9 8 20 0.331 2 0.0331
10 16 20 0.651 2 0.0651
11 17.5 20 1.001 2 0.1001
ChallengeC 10 120 2.2 12 0.2
Total 114.5 μl 19.2 ng/mlD 1.9 μg/mlD
In vitro desensitization protocol adapted from Sancho-Serra et al (26). AEach desensitization dose was spaced 10 minutes apart. BAdded to 50 μl cells.  
CFor desensitized cells not challenged with Ag, an equivalent volume of buffer was added. DFor desensitized cells not challenged with additional Ag, the 
final Ag concentration was 10 ng/ml for DNP-HSA and 1 μg/ml for OVA.
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Failure of desensitized MCs to degranulate in response to Ag 
challenge is due to their inability to mobilize Ca2+. Our studies of 
desensitized MCs so far revealed that the block in degranulation 
responses must occur further downstream of these signaling sub-
strates described above. A major requirement for MC degranu-
lation following the initial tyrosine phosphorylation cascade is 
Ca2+ mobilization (32). Therefore, we compared Ca2+ responses of 
desensitized and control MCs following Ag challenge. For these 
experiments, desensitized and control MCs were loaded with the 
Ca2+-sensitive dye Fluo-4 AM, and then exposed to Ag. Changes 
in Fluo-4 fluorescence corresponding to changes in intracellu-
lar Ca2+ were assessed using a confocal microscope. In contrast 
to control MCs, which showed a clear, sustained Ca2+ response, 
desensitized MCs failed to exhibit any change in intracellular Ca2+ 
levels upon Ag challenge (Figure 4A). Thus we hypothesized that 
the inability of desensitized MCs to degranulate was attributable 
to their failure to mobilize Ca2+. To underscore this conclusion, we 
exposed both control and desensitized MCs to ionomycin, a Ca2+ 
ionophore that complexes with and directly transports Ca2+ across 
the cell membrane, artificially increasing intracellular Ca2+ levels. 
Ionomycin elicited comparable degranulation responses in desen-
sitized and control MCs. Thus, artificially elevating intracellular 
Ca2+ in MCs was sufficient to overcome the block to degranulation 
caused by desensitization (Figure 4B).
IgE/FcεRI–mediated signaling occurs during DS of MCs. Since 
we observed no degranulation during the DS protocol, we pre-
dicted that escalating Ag doses could elicit signal transduction 
without Ca2+ mobilization. To test this notion, we prepared cell 
lysates sequentially from MCs 1 minute after each exposure to 
an escalating dose of Ag and subjected them to SDS-PAGE and 
Western blotting. As in Figure 3, we immunoblotted MC lysates 
for LYN, LAT, and ERK phosphorylation. Control MCs activated 
for 1 or 5 minutes were included for comparison (Figure 5A). As 
desensitization progressed, we observed increased phosphoryla-
tion of LAT and ERK, but not LYN, which was proportional to 
the cumulative Ag dose, though this change was statistically sig-
nificant only for ERK when densitometry was performed (Figure 
5A). Next, we investigated Ca2+ mobilization during desensitiza-
tion. Compared with MCs stimulated with Ag for the same length 
of time, desensitized cells exhibited limited Ca2+ signals, with 
observable spikes in fluorescence, but no indication of sustained 
Ca2+ mobilization (Figure 5B).
Since ERK, which is a key regulator of cytokine expression in 
MCs (33), was highly phosphorylated during desensitization, we 
investigated whether any de novo synthesis of select cytokines 
occurred during the protocol. To address this question, unstimu-
lated, Ag-stimulated, or desensitized MCs were stained for intra-
cellular CCL2 and TNF-α for FACS analysis. CCL2 seemed to be 
mostly preformed in all cells, but we found that there was signifi-
cant de novo synthesis of TNF-α in Ag-stimulated cells following 
Ag exposure, as evidenced by the increase in TNF-α–positive cells 
from baseline levels. In contrast, there was no difference in desen-
sitized cells (Figure 5C). Unexpectedly, when we analyzed mRNA 
transcript levels of Tnfa and Ccl2, desensitized cells had high lev-
els of transcripts for both, with an increase from baseline that was 
even significantly greater than that of Ag-stimulated MCs (Figure 
5D). To confirm whether secretion of cytokines was occurring, we 
assayed culture supernatants 24 hours after control treatment, 
desensitization, or Ag stimulation to analyze the cumulative cyto-
kine release via ELISA (Figure 5E). As expected, Ag-stimulated 
cells showed high secretion of both TNF-α (>100-fold over base-
line) and CCL2 (>10-fold over baseline). Interestingly, desensi-
tized cells showed significantly reduced cytokine secretion com-
pared with Ag-stimulated cells, but still showed modest production 
of cytokines compared with that seen with IgE alone (~30-fold over 
baseline for TNF-α and ~8-fold over baseline for CCL2). It thus 
appeared that while signaling leading to transcription of cytokines 
Figure 3. Desensitized cells have signaling responses to Ag. (A) 2 × 106 
BMMCs per sample were sensitized with IgE, desensitized (DS), or left 
untreated (Ag) before challenge with Ag for 0, 1, or 5 minutes. Cells were 
directly lysed in 4× Laemmli buffer for SDS-PAGE and immunoblotted for 
phospho- and total LYN, LAT, and ERK. Representative blots from  
4 experiments are shown. (B) Densitometry was performed on blots from 
4–5 experiments. Data were expressed as percentage of phosphorylated 
protein compared with total, then normalized to the positive control  
(5 minutes Ag activation). Data were analyzed via 1-way ANOVA and repre-
sent SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared with IgE group.
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is functional, and even enhanced, during desensitization, the lack 
of a Ca2+ response might be a factor contributing to the lack of max-
imal protein production, as sustained Ca2+ is required for optimal 
cytokine production in other cell types (34).
Desensitized MCs show distinct changes in F-actin distribution. If 
the absence of a sustained Ca2+ response explains the lack of MC 
degranulation during DS when subactivating doses of Ag were 
used, then why do desensitized MCs not degranulate in response 
to an optimal challenge dose of Ag? One possible explanation is 
that the desensitization process results in the redistribution of 
actin, an important regulator of the Ca2+ response. The spatial dis-
tribution of actin has been shown to be a critical determinant of 
Ca2+ mobilization in T cells (35), B cells (36), and MCs (23). To test 
this notion, we sought to investigate whether significant reorgani-
zation of F-actin occurred during the desensitization protocol, and 
consequently, whether this activity was responsible for impeding 
subsequent Ca2+ mobilization following exposure to Ag. To test 
this possibility, we investigated changes in F-actin distribution in 
IgE-sensitized MCs before and after desensitization by confocal 
microscopy. For these imaging studies, we substituted the MC-like 
cell line RBL-2H3 for BMMCs, as these cells were easy to trans-
fect and were adherent, making them easier to image. RBL-2H3 
cells stably expressing mCherry-tagged serglycin, a proteoglycan 
component of granules, were used to visualize granules. Unstim-
ulated, IgE-sensitized cells had clear spindle morphology with a 
peripheral distribution of F-actin and strong staining for granules, 
as indicated by serglycin-mCherry surrounded by CD63+ secre-
tory granule membranes. In Ag-stimulated cells, F-actin rapidly 
reorganized into large, distinct membrane ruffles by 5 minutes 
after challenge. Subsequently, F-actin depolymerized, and by 2 
hours redistributed into small aggregates dispersed throughout 
the cell (Figure 6A). These cells also exhibited a flattened mor-
phology with few intracellular granules, consistent with extensive 
degranulation (Figure 6A). Although desensitized MCs exhibited 
a flattened cell morphology, they remained fully granulated and, 
remarkably, exhibited extensive aggregates of F-actin throughout 
the cell (Figure 6A). When we examined MCs at various stages of 
desensitization, we found that the percentage of cells with exten-
sive F-actin reorganization increased as the desensitization pro-
cedure progressed (Supplemental Figure 3). Thus, compared with 
Ag-stimulated MCs, which exhibited extensive F-actin reorganiza-
tion after activation and which subsequently mostly disassembled 
by 2 hours, the F-actin structures in desensitized cells remained 
stable for at least 2 hours (Figure 6A). Notably, stimulation of 
desensitized MCs with normally activating doses of Ag failed to 
elicit appreciable changes to cellular F-actin distribution (Figure 
6A), indicating an inability to evoke further mobilization of actin.
Next, we investigated the underlying basis for the stability 
of reorganized actin in desensitized MCs and their intractabili-
ty to further remodeling in response to activating doses of Ag by 
focusing on the activation of distinct proteins involved in actin 
reorganization. Specifically, we assayed for the phosphorylation 
of cofilin, an actin-severing protein. Cofilin generates free actin 
filament ends to facilitate reorganization, and is inactivated by 
phosphorylation at the serine 3 position. In control MCs stimu-
lated with Ag, cofilin was rapidly dephosphorylated 1 minute after 
activation and highly rephosphorylated by 5 minutes after Ag 
activation, suggesting a brief activation window followed by neg-
ative feedback regulation during IgE/Ag activation. However, in 
desensitized MCs, the dephosphorylation and rephosphorylation 
of cofilin in response to Ag challenge, while observable, were not 
significant (Figure 6B), suggesting there may be some inhibition 
of cofilin-mediated actin turnover, possibly explaining the stabili-
ty of F-actin filaments in desensitized MCs. Thus, desensitization 
induces stable actin rearrangements in desensitized MCs that are 
unresponsive to further actin reorganization.
Specific recruitment of actin to desensitized receptors accounts for 
the Ag specificity of desensitization. If displacement of the cellular 
actin cytoskeleton is the underlying basis for MC desensitization, 
how does this proposed mechanism explain the characteristic Ag 
specificity of the desensitization protocol? To explain the antigen-
ic specificity of the desensitization protocol, we hypothesized that 
the actin reorganization that occurs during desensitization must 
be specific to the desensitized receptor, and not to heterologous 
Figure 4. Calcium mobilization is inhibited in desensitized cells. (A) IgE-sensitized BMMCs were left untreated (blue) or desensitized (red). After labeling 
with Fluo-4, cells were challenged with Ag (arrow) for 5 minutes. Responsiveness was confirmed by addition of ionomycin. Fluorescence was normalized 
to baseline. A representative graph is shown. AUC analyses were averaged from at least 4 independent experiments. (B) 5 × 105 BMMCs per sample in 
triplicate were desensitized or control treated before addition of 1 μg/ml ionomycin. Degranulation was measured via β-hexosaminidase assay. Data were 
analyzed via 2-tailed Student’s t test. Error bars represent SEM. **P < 0.01.
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steady-state levels by 2 hours (Figure 7, B and C). This finding is 
in agreement with earlier studies showing maximal association of 
the actin cytoskeleton with IgE/FcεRI approximately 30 minutes 
after Ag stimulation of MCs (38, 39).
Next, we investigated whether a similar association could 
be observed between β-actin and desensitized FcεRI following 
desensitization of MCs with each of the 2 antigens. For this, one 
of the IgE clones in the sensitization mixture (anti-OVA or anti-
DNP IgE) was biotinylated, while the other was left IgE unlabeled. 
Thus, MCs were sensitized with a mixture of IgE where only IgE of 
one specificity was biotinylated but not the other. After desensiti-
zation or Ag challenge with either Ag (~2 hours of incubation), cell 
lysates were prepared and immunoprecipitated with streptavidin 
beads, which only pulled down the biotinylated IgE and associated 
complexes, leaving the unlabeled IgE in the flow-through. A recip-
rocal experiment was also performed in which the IgE clone being 
biotinylated was switched. Unsensitized BMMCs were included in 
both experiments as negative controls. Western blots of the immu-
noprecipitates from both sets of experiments revealed β-actin in 
the pulldown of biotinylated IgE desensitized with its correspond-
ing Ag, but not when heterologous Ag was used for desensitiza-
tion (Figure 7D). Notably, the amount of β-actin associated with 
desensitized IgE/FcεRI was markedly higher than that associated 
with Ag-challenged samples at that time point (~2 hours). Taken 
together, these observations suggest that Ag specificity may be 
achieved, at least in part, by specific association of the actin cyto-
skeleton with desensitized receptors. This finding also suggests 
that the F-actin aggregates in desensitized MCs (Figure 6A) may 
be at least partly associated with IgE/FcεRI.
Manipulation of the actin cytoskeleton of MCs reverses desensi-
tization in vitro and in vivo. To further demonstrate the contribu-
tion of the actin cytoskeleton to MC desensitization, we attempt-
ed to reverse actin rearrangement in desensitized MCs back to 
their steady-state arrangement, and then examined whether this 
activity speedily restored their ability to mediate Ca2+ flux and 
to degranulate following exposure to Ag. To this end, we used a 
cell-permeable peptide construct of the Salmonella effector SptP, 
SptPC481S-TAT (40). SptP is secreted by Salmonella during infec-
tion, and has 2 effector domains: a phosphatase domain and a 
GAP domain. Notably, the GAP domain is necessary and suffi-
cient to reverse the actin cytoskeletal changes caused by bacterial 
entry, which include ruffling and membrane protrusions, by inhi-
bition of the small GTPases CDC42 and RAC1 (41). We have pre-
viously shown that recombinant SptPC481S-TAT with the catalyti-
cally inactive phosphatase domain, but a functional GAP domain, 
did not affect IgE-mediated MC degranulation (40). Addition-
ally, since we observed that RAC1 is activated in desensitized 
MCs compared with IgE-sensitized cells (Supplemental Figure 
6), we examined the effect of SptPC481S-TAT on this GTP-binding 
protein. We found that this agent reduced active RAC1 in both 
desensitized and unstimulated IgE-sensitized MCs to undetect-
able levels. Thus, SptPC481S-TAT appears to be acting on MCs via a 
RAC1-dependent pathway.
To observe cytoskeletal changes in MCs exposed to SptPC481S- 
TAT, IgE-sensitized serglycin-mCherry RBL-2H3 cells on cov-
erslips were desensitized or control treated, then treated with 
SptPC481S-TAT or control. Thirty minutes later, cells were chal-
receptors bound to IgE specific for a different Ag. These heterolo-
gous complexes should then be unimpeded to trigger MC degran-
ulation. To validate this notion, we sensitized RBL-2H3 cells with 
a mixture of IgE directed at 2 distinct antigens: OVA and dini-
trophenyl (DNP). To demonstrate that MC desensitization was 
Ag specific, we desensitized MCs with one Ag and examined the 
degranulation response to heterologous Ag. Groups of MCs were 
simultaneously sensitized with anti-DNP and anti-OVA IgE anti-
bodies, then desensitized with OVA or DNP-HSA, or left unde-
sensitized (Figure 7A). To achieve similar degranulation levels to 
Ag, a 1:5 mixture of anti-DNP/anti-OVA IgE was used to sensitize 
cells (Supplemental Figure 4). The variously treated groups were 
then subjected to Ag challenge with either OVA or DNP-HSA. We 
found that desensitization of MCs with OVA did not significantly 
decrease the MC degranulation response to the heterologous Ag 
DNP (Figure 7A). For MCs desensitized with DNP, while there was 
a significant reduction in response to OVA, more than 75% of the 
degranulation response to OVA was still preserved. This confirms 
that desensitization is largely Ag specific. Previous reports have 
noted that cross-linking of IgE/FcεRI results in their association 
with the actin cytoskeleton (37–39), which might impact down-
stream function. We thus wondered whether a similar phenome-
non could explain the Ag specificity of DS. We hypothesized that 
actin association with IgE/FcεRI also occurred during DS and, 
importantly, was specific to the desensitized receptor. Firstly, we 
confirmed that there was an association between actin and IgE/
FcεRI following MC activation. We sensitized BMMCs with bioti-
nylated anti-OVA or anti-DNP IgE, then challenged them with 
the corresponding Ag. We previously confirmed that biotinylated 
IgE was functional and could elicit degranulation (Supplemental 
Figure 5). We prepared cell lysates at various time points after Ag 
stimulation and immunoprecipitated the lysates using streptavi-
din agarose beads to pull down the biotinylated IgE and associated 
FcεRI and other proteins in the complex, such as β-actin. Immu-
noblotting revealed that β-actin was only weakly associated with 
IgE/FcεRI at 0 minutes, then became maximal at 30 minutes after 
activation, with levels of immunoprecipitated β-actin returning to 
Figure 5. Signal transduction but no calcium mobilization during 
RDS. (A) 2 × 106 BMMCs per sample were sensitized with IgE before Ag 
challenge for 0, 1, or 5 minutes (first 3 lanes) or desensitized (lanes 4–14), 
with samples collected 1 minute after each dose was added. Samples 
were immunoblotted for phospho- and total LYN, LAT, and ERK. Blots 
are representative of at least 3 experiments. For densitometry, data were 
expressed as percentage of phosphorylated protein compared with total, 
then normalized to the positive control (5 minutes Ag). Data were ana-
lyzed via 1-way ANOVA with comparisons with IgE (Dunnett’s post-test). 
(B) BMMCs were adhered to Cell-Tak–coated (Corning) glass-bottomed 
plates for calcium imaging. Cells were stimulated with Ag or desensi-
tized (DS), with successive doses added every 5 minutes (arrows). AUC 
analyses were averaged from 4–5 independent experiments. (C–E) 5 × 105 
IgE-sensitized BMMCs per sample in triplicate were desensitized (DS), 
antigen challenged (Ag), or untreated (IgE). (C) BMMCs were incubated 
with brefeldin A for 8 hours before intracellular staining for FACS. (D) RNA 
was isolated from cell pellets for cDNA preparation. Quantitative RT-PCR 
was performed using primers for Ccl2 and Tnfa and normalized to Actb 
expression. (E) Cell supernatants after 24 hours were analyzed for CCL2 
and TNF-α secretion. Data were expressed as fold over IgE-only controls. 
Data were analyzed via 1-way ANOVA (A and C–E) or Student’s t test (B). 
Data represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 6. Distinct actin reorganization in desensitized cells. (A) Serglycin (SG)–mCherry (red) RBL-2H3 cells were plated on coverslips before desen-
sitization and/or challenge with Ag for 5 minutes followed by fixation and staining for CD63 (blue) and F-actin (green). Images are representative of 
at least 3 independent experiments. Scale bars: 10 μm. (B) 2 × 106 BMMCs per sample were desensitized (DS) or untreated (Ag) before challenge with 
Ag for 0, 1, or 5 minutes. Lysates were immunoblotted for phosphorylated and total cofilin. Blots represent at least 4 experiments. Densitometry data 
were expressed as percentage phosphorylated protein compared with total, then normalized to control (IgE). Data were analyzed via 1-way ANOVA. 
Data represent SEM. *P < 0.05.
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were incubated with 10 μg/ml SptPC481S-TAT or PBS for 30 minutes 
and then challenged with Ag. As previously reported (40), SptPC481S- 
TAT treatment did not affect IgE/Ag stimulation or maximal 
degranulation elicited by ionomycin. Interestingly, incubation of 
desensitized cells with SptPC481S-TAT prior to Ag challenge restored 
their ability to degranulate in response to Ag (Figure 9B), confirm-
ing that SptPC481S-TAT treatment was sufficient to reverse the inhibi-
tory effect of desensitization on Ag-mediated degranulation.
Finally, we sought to confirm our in vitro findings in our in vivo 
model of rapid desensitization. IgE-sensitized mice were orally 
desensitized as in Figure 1, or gavaged with PBS control, before 
being injected i.p. with 50 μg SptPC481S-TAT or an equivalent vol-
ume of PBS. One hour later, mice were challenged i.p. with 500 μg 
Ag. IgE-sensitized mice showed a dramatic (~5°C) decrease in core 
body temperature 30 minutes after challenge with Ag that was 
unaffected by SptPC481S-TAT treatment (Figure 9C). In contrast, 
desensitized mice were significantly protected from anaphylaxis, 
showing a less than 2°C drop in core body temperature by 30 min-
utes after challenge. Injection of SptPC481S-TAT into desensitized 
mice abolished this protection and rescued the anaphylactic phe-
notype. Cumulatively, our in vitro and in vivo data suggest that 
reversal of the actin cytoskeleton remodeling induced by the DS 
protocol on MCs is sufficient to restore their sensitivity to Ag.
Discussion
Our studies provide new insights into the underlying mechanism 
of DS in MCs, which could be of immediate benefit in the design of 
novel strategies to induce or prolong the desensitized state of MCs 
lenged with Ag, then fixed for immunofluorescence staining with 
anti-CD63 antibody and fluorescent phalloidin. Treatment with 
SptPC481S-TAT restored desensitized cells to the peripheral dis-
tribution in control RBL-2H3 cells, reducing the spreading and 
membrane ruffling seen in desensitized cells (Figure 8 and Sup-
plemental Figure 7). SptPC481S-TAT treatment also enabled MCs 
to degranulate, as seen by the exocytosis of serglycin-containing 
secretory granules in RBL cells (Figure 8). Thus, similarly to how 
bacterial SptP “resets” the perturbed actin cytoskeleton in Sal-
monella-infected cells, SptPC481S-TAT restores actin to a basal-like 
distribution in MCs. This allows for treated cells to respond to 
Ag, both in Ag-mediated actin reorganization and also seemingly 
to discharge granules.
Based on our findings, we predicted that restoring actin to the 
basal state using SptPC481S-TAT would also now allow sustained 
Ca2+ influx in desensitized cells by rescuing actin modulation 
of the Ca2+ response. To test this, BMMCs were desensitized or 
untreated, then incubated with SptPC481S-TAT or PBS before label-
ing with Fluo-4 for Ca2+ imaging. In control cells, untreated and 
SptPC481S-TAT–treated BMMCs had comparable levels of Ca2+ 
flux, while desensitized cells had no response to Ag challenge. 
Ca2+ flux in response to Ag was partially rescued in desensi-
tized, SptPC481S-TAT–treated cells (Figure 9A), with a slight delay. 
This indicated that actin reorganization via inhibition of RAC1/
CDC42 by SptPC481S-TAT could partially rescue the inhibition of 
Ca2+ flux caused by desensitization.
Next we sought to quantitate the effects of SptPC481S-TAT treat-
ment on degranulation response of MCs. Control or desensitized cells 
Figure 7. Antigen specificity of desensitization. (A) RBL-2H3 cells were sensitized with a 1:5 ratio of anti-DNP to anti-OVA IgE, then desensitized to 
DNP-HSA or OVA before challenge with DNP-HSA (10 ng/ml) or OVA (1 μg/ml). Data were analyzed via 1-way ANOVA and are representative of at least 3 
independent experiments. (B and C) 107 BMMCs per sample were sensitized with biotinylated IgE, then challenged with Ag for the indicated times. Lysates 
were immunoprecipitated with streptavidin beads and blotted for β-actin and FcεRIγ. (D) 107 BMMCs per sample were sensitized with a mixture of bioti-
nylated and unbiotinylated IgE, then desensitized or challenged with Ag for the same amount of time (~2 hours). Lysates were then immunoprecipitated 
with streptavidin beads and blotted for β-actin and FcεRIγ. Data represent SEM. ***P < 0.001.
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sufficient IgE remained on cell surfaces to bind Ag after the DS 
protocol (Figure 2, A and B). This observation is consistent with 
earlier reports suggesting that ligation of as little as 10% of sur-
face FcεRI is sufficient for a maximal MC degranulation response 
to Ag (43). Our own studies titrating BMMCs with various dilu-
tions of IgE showed that maximal degranulation in response to Ag 
could be induced even with relatively low amounts of IgE bound 
to receptors (Supplemental Figure 1). Additionally, Khodoun et al. 
achieved desensitization of MCs using antibodies against FcεRI, 
without causing complete internalization of surface receptors, 
once again suggesting that complete depletion of surface FcεRI 
was not necessary for desensitization (44). Indeed, while we 
observed IgE internalization during Ag activation and desensiti-
zation, this typically was not complete, as Ag-activated cells still 
had approximately 50% of baseline cell surface IgE, whereas 
desensitized cells had approximately 70% of baseline cell surface 
IgE (Figure 2D). Secondly, we observed in vitro that desensitized 
MCs eventually recovered their ability to degranulate in response 
to Ag even without additional exposure to IgE (Figure 2C). Our 
finding that IgE/FcεRI complexes on desensitized MCs upon 
exposure to activating doses of Ag were still capable of phosphor-
ylating several key signaling substrates also contrasts with the 
for therapeutic purposes. Earlier reports have suggested that DS is 
the result of IgE internalization by MCs and basophils, thus prevent-
ing further responses to Ag (25, 42). These studies supposed that 
during DS, application of small, subactivating doses of Ag to MCs 
induced internalization of IgE/FcεRI complexes without triggering 
any degranulation events. For example, Shalit and Levi-Schaffer (42) 
linked refractoriness of MCs to Ag with desensitization, and hypoth-
esized that progressive internalization of IgE with each Ag dose 
likely reduced the ability of the MCs to respond to the next. A more 
recent study by Oka et al. (25) similarly concluded that DS must 
occur through IgE internalization, as inhibiting IgE/FcεRI internal-
ization by cold incubation during DS prevented effective desensiti-
zation, since these MCs degranulated when brought back to 37°C. 
On the other hand, Sancho-Serra et al. (26) observed that desensi-
tized MCs had inhibited early and late MC activation responses, as 
well as impaired internalization of IgE/FcεRI complexes, suggesting 
a different explanation for MC hyporesponsiveness.
In the present study, at least 2 distinct observations suggest 
that depletion of IgE from the MC surface is an inadequate expla-
nation for the hyporesponsiveness of desensitized MCs to acti-
vating doses of Ag. Firstly, we observed that desensitized MCs, 
both ex vivo and in vitro, are able to bind Ag, suggesting that 
Figure 8. Manipulation of the actin cytoskeleton reverses actin changes caused by desensitization. IgE-sensitized serglycin-mCherry (red) RBL-2H3 cells 
were plated onto covered coverslips and desensitized, then treated with control or 20 μg/ml SptPC481S-TAT for 45 minutes before challenge with Ag for 5 
minutes followed by fixation and staining for CD63 (blue) and F-actin (green). Images are representative of 3 independent experiments. Scale bars: 10 μm.
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We have deduced that the reason for the lack of a Ca2+ response 
in desensitized MCs in spite of their capability to mediate FcεRI- 
mediated signal transduction is the marked alteration of the cellular 
distribution of the actin cytoskeleton. In our hands, serial exposure 
of MCs to increasing amounts of subactivating doses of Ag during 
DS resulted in the significant redistribution of F-actin. Remarkably, 
the remodeled actin cytoskeleton persisted even after DS and when 
the desensitized cells were challenged with a further activating dose 
of Ag, suggesting these actin complexes were highly stable.
There is now a growing realization that actin, specifically its 
organization and spatial distribution, plays a critical role in regu-
lating Ca2+ mobilization in a variety of cell types, including T cells 
(20), platelets (46), and, importantly, MCs (47). Although the pre-
cise mechanism of how the actin cytoskeleton modulates Ca2+ flux 
in MCs remains to be elucidated, studies in other cell types suggest 
that actin modulates the association of the endoplasmic reticulum 
Ca2+ sensor stromal interaction molecule 1 (STIM1) with the plasma 
earlier supposition that desensitized MCs were refractory to sig-
nal transduction. Thus, our findings do not concur with any of the 
earlier conclusions regarding the basis for MC desensitization fol-
lowing DS. Instead, our studies suggest that MC hyporesponsive-
ness is attributable, at least in part, to abrogation of Ca2+ mobili-
zation, a critical determinant of both degranulation and cytokine 
production responses in MCs (32).
It is noteworthy that the behavior of desensitized MCs is anal-
ogous to that of a mutant RBL-2H3 cell line, which was found to be 
defective in its ability to mobilize Ca2+ but retained normal tyrosine 
phosphorylation of key signaling substrates following engagement 
of FcεRI. In spite of their capability to transduce signals, these 
mutant cells, like desensitized MCs, were incapable of a degran-
ulation response (45). Additional data linking hyporesponsiveness 
of MCs to their inability to mount a Ca2+ response come from the 
observation that desensitized MCs can be induced to degranulate 
by artificial induction of Ca2+ influx using ionomycin (Figure 4B).
Figure 9. Manipulation of the actin cytoskeleton reverses desensitization in vitro and in vivo. (A) Control (C481S-Ag) or desensitized (C481S-DS) BMMCs 
were treated with SptPC481S-TAT (C481S-Ag, C481S-DS) or buffer (control Ag, control DS/Ag) for 30 minutes before being loaded with Fluo-4. After measure-
ment of baseline fluorescence for 2 minutes, cells were activated with 10 ng/ml Ag and ionomycin. A representative graph is shown. AUC was averaged 
from 4–5 independent experiments. (B) Control (IgE/Ag, buffer, and ionomycin) or desensitized (DS/Ag) BMMCs were treated with 10 μg SptPC481S-TAT 
(C481S) or untreated before challenge with Ag, buffer, or ionomycin for β-hexosaminidase assay. Data are representative of at least 3 independent exper-
iments. (C) IgE-sensitized mice were orally desensitized (DS, DS-C481S) or given PBS (Ag, Ag-C481S). Mice were then injected with 50 μg SptPC481S-TAT 
(Ag-C481S, DS-C481S) or equal volume PBS (Ag, DS). One hour later, mice were challenged i.p. with 500 μg Ag. Rectal temperatures were measured every 
15 minutes for 30 minutes. Results were pooled from 2 independent experiments (n = 10). Data were analyzed via 2-way ANOVA (A and B) and repeated- 
measures ANOVA (C). Data represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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correctly the underlying basis for MC desensitization. Our stud-
ies have uncovered, at least in part, the basis for DS-induced MC 
desensitization. While we cannot rule out the possibility of other 
contributing factors such as negative regulatory signaling, our 
observations strongly indicate a role for aberrant actin remodeling 
during desensitization and the resulting inhibition of Ca2+ mobili-
zation in the inhibition of MC degranulation in response to subse-
quent Ag challenge. We also present a model of passive systemic 
anaphylaxis and oral desensitization in vivo. While our model can-
not be considered wholly mast cell specific due to the caveats of 
the Wsh mouse (51), our in vitro and in vivo data indicate that this 
cell type is likely to be the main effector in desensitization. Addi-
tionally, our oral in vivo desensitization model could be of value 
for future studies on mechanisms of desensitization, as it is a more 
convenient and humane way to serially administer Ag compared 
with repeated-injection protocols. We believe these studies pro-
vide valuable insights for the development of new strategies to 
either induce MC desensitization or prolong its effects.
Methods
Antibodies, cell lines, and reagents. Anti–phospho-LAT (Y226) (catalog 
07-295), anti-FcεRIγ (06-727), and anti-LAT (06-807) antibodies were 
from Upstate Technology. Phospho-LYN (Y396) antibody was from 
Abcam (ab40660). Antibodies against phospho-cofilin (mAb 3313) 
and total cofilin (mAb 5175), as well as total LYN (catalog 2796), were 
from Cell Signaling Technologies. Antibodies against phospho-ERK 
(sc-7383) and ERK2 (sc-154) were from Santa Cruz Biotechnology. 
Anti–β-actin antibody was from Sigma-Aldrich (clone AC-74). BMMCs 
were obtained from femur bone marrow of 8-week-old C57BL/6 mice 
and cultured in BMMC medium (RPMI-1640 with l-glutamine, 10% 
heat-inactivated FBS, 10 mM HEPES, 1 mM sodium pyruvate, 1× non-
essential amino acids, and 100 U/ml penicillin/streptomycin) at a den-
sity of 0.5 × 106 to 1 × 106 cells/ml with 5 ng/ml recombinant murine 
IL-3 (R&D Systems) and 5% to 10% stem cell factor-containing super-
natant from CHO-KL cells for 4–6 weeks until maturation. CHO-KL 
cells were a gift from M. Arock (Laboratoire de Biologie et Pharmacol-
ogie Appliquée, Paris, France). RBL-2H3 cells were purchased from 
ATCC and maintained in MEM with Earle’s salts, l-glutamine, 1 mM 
sodium pyruvate, and 15% heat-inactivated FBS. TNP(12)-OVA was 
obtained from Biosearch Technologies. All other chemical reagents 
were from Sigma-Aldrich unless otherwise specified.
In vitro desensitization and β-hexosaminidase assay. All experi-
ments were repeated with both anti-DNP IgE (SPE-7, Sigma-Aldrich) 
and anti-TNP IgE (BD Biosciences) unless otherwise stated. BMMCs 
or RBL-2H3 cells were sensitized with 0.25–0.5 μg/ml IgE for 4 hours 
to overnight and washed 3 times before the start of the experiment. All 
assays were done in Tyrode’s buffer (135 mM NaCl, 5.5 mM glucose, 5 
mM KCl, 1 mM MgCl2, 1.3 mM CaCl2, 0.5% BSA, pH 7.4) unless oth-
erwise specified. For β-hexosaminidase assay, IgE-sensitized BMMCs 
were seeded at 3 × 105 to 5 × 105 cells per well in V-bottomed 96-well 
plates on the day of the experiment. RBL-2H3 cells were seeded at 
5 × 104 cells per well in MEM with IgE in 96-well flat-bottomed plates 
overnight. Assays were then performed as previously described (40).
Intracellular cytokine staining, ELISAs, and RT-PCR. In each case, 
5 × 105 BMMCs per sample were sensitized with anti-DNP IgE and 
desensitized or challenged with Ag, then incubated in 3 μg/ml brefel-
din A (eBioscience) for an additional 6 hours (total time ~8 hours). The 
membrane Ca2+ channels ORAI1 and TRPC (48). This association 
typically precedes the formation of a functional Ca2+ release–acti-
vated channel (CRAC) on the plasma membrane that initiates the 
influx of extracellular Ca2+. Support for this proposed role of actin 
rearrangement comes from our observation that upon reversing 
actin cytoskeletal organization in desensitized MCs with a cell-per-
meable construct of the Salmonella effector SptP, SptPC481S-TAT, we 
could restore its Ca2+ mobilization and degranulation activity as 
well as the anaphylactic phenotype in desensitized mice. This is a 
highly accelerated recovery of degranulation in desensitized MCs, 
which without further manipulation took 48 hours to regain respon-
siveness to Ag challenge (Figure 2C). In these recovered desensi-
tized cells, we have also observed reversion of F-actin organization 
to the naive IgE-sensitized phenotype (data not shown), further 
suggesting that proper localization of actin is important for IgE/Ag 
activation. Presumably, the effect of SptPC481S-TAT on desensitized 
MCs occurs via the known GAP activity of SptPC481S-TAT on RAC1/
CDC42, as we have observed that this pathway is activated during 
desensitization and is inhibited by SptPC481S-TAT (Supplemental 
Figure 6). Curiously, RAC1/CDC42 has been postulated to have a 
positive rather than a negative regulatory effect on Ca2+ mobiliza-
tion in MCs as would be expected from our model (49). Conceiv-
ably, RAC1/CDC42 could be exerting its effect in our system via 
other pleiotropic downstream effects on actin cytoskeletal rear-
rangement (Figure 8), possibly via cofilin inactivation (phosphory-
lation) downstream of PAK kinases (50), rather than through direct 
effects on Ca2+ mobilization via IP3 production (49). 
Our observed absence of sustained Ca2+ mobilization during the 
desensitization process (Figure 5B) also explains the lack of degran-
ulation during DS, despite the incomplete displacement of the actin 
cytoskeleton prior to completion of desensitization. We postulate 
that the subactivating doses of Ag applied during DS did not result 
in a sufficient magnitude of signal transduction to provoke a sus-
tained Ca2+ flux, while allowing for progressive actin cytoskeletal 
rearrangements such that the fully desensitized MC was no longer 
able to respond appropriately to activating doses of Ag.
We have also been able to confirm the Ag specificity of the 
desensitization protocol (Figure 7A). While a model of desensiti-
zation that involves the actin cytoskeleton may appear nonspecific 
with regard to which receptors are impacted, there is specificity in 
the way desensitized receptors interact with the actin cytoskele-
ton, which could, at least in part, explain the Ag specificity of DS. 
We found that desensitization to 1 particular Ag resulted in the 
specific association of actin with homologous, and not heterolo-
gous, desensitized receptors (Figure 7D). Since the actin cytoskel-
eton can regulate Ca2+ responses, the stable aggregates of actin fil-
aments in desensitized MCs could negatively regulate the ability 
of the desensitized receptor to mediate a Ca2+ response. Although 
an association between actin and FcεRI was observed during Ag- 
induced MC degranulation, this interaction was transient (Figure 
7, B and C), and, importantly, it seemed to peak at least 30 minutes 
after activation, which suggests that rather than promoting signal 
transduction, this association between FcεRI and actin may serve 
to terminate specific signaling processes.
With the ever-increasing incidence of allergic reactions in the 
population to constituents in food and essential drugs and the lack 
of alternatives to DS protocols, there is a dire need to understand 
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immunoprecipitation lysis/wash buffer (Pierce) containing protease 
inhibitors. After clearing of cell debris, 80 μl of streptavidin agarose 
bead slurry (Thermo Fisher Scientific) was added to 500 μg of total 
protein and incubated at 4°C for 2 hours. The beads were then washed 
5 times with lysis/wash buffer, then boiled with 50 μl 2× SDS-PAGE 
buffer before electrophoresis. For analysis of phosphotyrosine signal-
ing, 2 × 106 BMMCs per sample were lysed directly in 4× Laemmli 
sample buffer containing β-mercaptoethanol and immediately boiled 
for 5 minutes. Samples were loaded on 4%–20% acrylamide gels for 
SDS-PAGE before transfer and immunoblotting with respective anti-
bodies to phospho-proteins. In some cases, after exposing of blots, 
membranes were stripped and reprobed for total protein.
Calcium measurements. BMMCs in RPMI were loaded with 1 μM 
Fluo-4 AM (Life Technologies) with 0.02% Pluronic F-127 for 10 
minutes at 37°C, washed twice in Tyrode’s buffer, and recovered in 
Tyrode’s buffer (135 mM NaCl, 5.5 mM glucose, 5 mM KCl, 1 mM 
MgCl2, 1.3 mM CaCl2, 0.5% BSA, pH 7.4) for 15 minutes at 37°C before 
imaging. Images were acquired every 5 seconds on an Andor XD revo-
lution spinning disk confocal microscope (Olympus), and fluorescence 
was quantitated using MetaMorph software (Molecular Devices). Data 
were expressed as fold over baseline fluorescence. Cells that moved out 
of focus during the experiment or did not respond to a final administra-
tion of ionomycin were excluded from analysis.
Constructs, transfection, and protein purification. We used a His-
tagged, phosphatase-inactive, cell-permeable form of SptP (SptPC481S- 
TAT) that has been described (40). Recombinant His-tagged SptPC481S- 
TAT expressed in BL21-Gold–competent cells (Agilent Technologies) 
was purified using a cobalt column (His Gravitrap Talon, GE Health-
care) and extensively dialyzed in PBS to remove salts before concen-
trating and quantitation of protein. Serglycin-mCherry–expressing 
RBL-2H3 cells were created by retroviral transduction. Transduced 
cells were selected with 500 μg/ml geneticin.
Statistics. All data are expressed as SEM. Significance was calcu-
lated by unpaired 2-tailed Student’s t test to assess data with 2 groups 
or by 1- or 2-way ANOVA and Tukey’s multiple comparison or Bonfer-
roni post-tests, as appropriate, for all other experiments. Results were 
considered significant if P was less than 0.05. All graphs and analyses 
were done with Prism (GraphPad) software.
Study approval. All studies were performed with the approval of 
the Duke University Animal Care and Use Program.
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cells were then washed, permeabilized, blocked with 0.25% saponin 
in 1% BSA in PBS, and stained for intracellular CCL2 and TNF-α using 
FITC anti–mouse CCL2 and allophycocyanin  anti–mouse TNF-α (eBio-
science) before assay via FACS. To assay cytokine secretion, untreated, 
desensitized, or Ag-challenged BMMCs (5 × 105 BMMCs per sample 
in triplicate) were incubated in RPMI for 24 hours. Cell culture super-
natants were diluted 1:5 and assayed for CCL2 and TNF-α using a kit 
(eBioscience) according to the manufacturer’s instructions. For cyto-
kine mRNA quantitation, RNA was prepared from 5 × 105 BMMCs per 
sample in triplicate. RNA was isolated using an RNeasy purification sys-
tem (Qiagen). cDNA was synthesized using the iScript cDNA synthesis 
kit (Bio-Rad). SYBR Green and iCycler machine (Bio-Rad) were used for 
real-time PCR. Primers were obtained from IDT-DNA for β-actin (Actb): 
5′-TGAGAGGGAAATCGTGCGTGACAT, 5′-ACCGCTCATTGAC-
GATAGTGATGA; CCL2: 5′-AGCAGGTGTCCCAAAGAAGCTGTA, 
5′-AAAGGTGCTGAAGACCTTAGGGCA; Tnfa: 5′-TCTCATGCAC-
CACCATCAAGGACT-3′, 5′-ACCACTCTCCCTTTGCAGAACTCA-3′. 
All target gene RNA expressions were normalized to Actb expression. 
Data were expressed as fold over IgE-only controls.
Mice and in vivo model of DS and systemic anaphylaxis. Six- to eight-
week-old female C57BL/6 mice were purchased from The Jackson Lab-
oratory. All experiments were performed in accordance with Duke Uni-
versity’s Animal Care and Use Committee. Mice were sensitized i.p. with 
10 μg of anti-TNP IgE (BD Pharmingen) in 100 μl sterile PBS 1–7 days 
before the experiment. Desensitization doses were delivered via oral 
gavage in a volume of 100 μl in saline and were spaced 30 minutes apart. 
Control animals received PBS gavage. For Ag challenge, mice were given 
500 μg of TNP-OVA (Protein Sciences) i.p. Core body temperature was 
monitored with a rectal thermometer before each desensitization dose, 
and every 15 minutes after challenge with Ag for up to 2 hours. For assay 
of peritoneal cells via FACS or histology, mice were lavaged with 4 ml 
cold PBS containing 1 mM EDTA. To assay Ag binding, 3 × 106 peritoneal 
lavage cells were blocked in 1% BSA in PBS before incubation with 100 
ng/ml Alexa Fluor 647–labeled TNP-OVA prepared using a protein label-
ing kit (Molecular Probes) according to the manufacturer’s instructions. 
After incubation on ice for 1 hour with labeled Ag, cells were washed 4 
times in cold PBS before fixation with 4% paraformaldehyde and assay 
via FACS. For visualization of MC degranulation, 100 μl of peritoneal 
lavage was cytospun onto charged glass slides at 600 rpm for 5 minutes. 
Slides were fixed in Carnoy’s fixative (60% ethanol, 30% chloroform, 
10% glacial acetic acid) before staining with toluidine blue dye.
Immunofluorescence. RBL-2H3 cells were seeded onto clean glass 
coverslips in IgE-containing medium. Cells were then stained for cyto-
skeleton using methods previously described (52). Briefly, cells were 
rinsed in cytoskeletal buffer (CSK buffer) (0.1 MES, pH 6.9, 2 mM 
EGTA, 2 mM MgCl2, 4% polyethylene glycol 8000) before being fixed 
with 3.7% formaldehyde in CSK buffer, then extracted with 0.5% Tri-
ton-X in CSK buffer before staining with antibodies. Coverslips were 
mounted in ProLong Gold (Life Technologies) to preserve fluorescence 
before imaging using a Nikon ECLIPSE TE200 laser scanning confocal 
microscope, using a sequential channel series approach to avoid spec-
tral overlapping. Images were edited using ImageJ software (NIH).
Biotin labeling, immunoprecipitation, SDS-PAGE, and protein 
immunoblotting. IgE was biotinylated using a kit (Thermo Fisher Sci-
entific) according to the manufacturer’s instructions. For immuno-
precipitation of biotinylated IgE, 107 BMMCs sensitized with a mix-
ture of biotinylated and unbiotinylated IgE per sample were lysed in 
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